Kintegral Advisory LLC Trims Position in Becton, Dickinson and Company (NYSE:BDX)

Kintegral Advisory LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.4% during the 4th quarter, Holdings Channel reports. The fund owned 6,426 shares of the medical instruments supplier’s stock after selling 299 shares during the period. Kintegral Advisory LLC’s holdings in Becton, Dickinson and Company were worth $1,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BDX. Redmond Asset Management LLC boosted its holdings in Becton, Dickinson and Company by 115.3% in the fourth quarter. Redmond Asset Management LLC now owns 6,453 shares of the medical instruments supplier’s stock valued at $1,464,000 after purchasing an additional 3,456 shares during the last quarter. Arcadia Investment Management Corp MI boosted its stake in shares of Becton, Dickinson and Company by 44.1% in the fourth quarter. Arcadia Investment Management Corp MI now owns 37,488 shares of the medical instruments supplier’s stock worth $8,505,000 after buying an additional 11,472 shares during the last quarter. Nicholson Wealth Management Group LLC grew its holdings in Becton, Dickinson and Company by 123.5% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 6,380 shares of the medical instruments supplier’s stock worth $1,447,000 after acquiring an additional 3,526 shares during the period. Mattern Capital Management LLC grew its holdings in Becton, Dickinson and Company by 6.0% during the fourth quarter. Mattern Capital Management LLC now owns 32,359 shares of the medical instruments supplier’s stock worth $7,341,000 after acquiring an additional 1,843 shares during the period. Finally, Concurrent Investment Advisors LLC raised its position in Becton, Dickinson and Company by 15.4% during the fourth quarter. Concurrent Investment Advisors LLC now owns 10,750 shares of the medical instruments supplier’s stock valued at $2,439,000 after acquiring an additional 1,438 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roland Goette sold 638 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,544 shares of company stock valued at $2,370,309 in the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

BDX opened at $227.54 on Friday. The firm’s fifty day simple moving average is $232.90 and its two-hundred day simple moving average is $233.27. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a market cap of $65.33 billion, a price-to-earnings ratio of 37.80, a PEG ratio of 1.64 and a beta of 0.40. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Analysts Set New Price Targets

A number of brokerages have recently commented on BDX. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Barclays upped their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Piper Sandler raised their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.